Leading Brands

Brand building is at the core of our marketing strategy. A significant proportion of our revenues is derived from brands which are among top 10 in their respective subgroups. We derive a higher proportion of our revenues from our top 15 and top 25 mother brand groups, as compared to the average of the top 25 players in the IPM

  Top 15 Mother Brand Groups Revenue Contribution Top 25 Mother Brand Groups Revenue Contribution
Eris Lifesciences 74.2% 83.7%
Average of Top 25 Companies in IPM 59.0% 70.5%

Source: IMS TSA MAT, March 2018

Top 15 Brands

Brand Year of launch Indication Subgroup(including combinations) Sales Value in INR Millions Brand CAGR (FY 13-18) Market CAGR (FY 13-18) Prescription rank
GLIMISAVE 2007 Anti – Diabetes Glimepiride 1,835.3 24.4% 17.2% 3
ERITEL 2008 Hypertension Telmisartan 1,023.0 22.3% 20.1% 4
RENERVE 2003 Neuropathy Methylcobalamin and combinations 801.0 15.5% 13.8% 3
TAYO 2011 Vit. D deficiency in Metabolic disorders Vitamin D 530.5 6.5% 18.6% 5
RABONIK 2008 Gastroenterology Rabeprazole 477.2 4.6% 11.9% 12
OLMIN 2010 Hypertension Olmesartan 475.2 27.3% 17.3% 3
REMYLIN 2007 Diabetic Neuropathy Mecobalamin+Colecalciferol 470.0 5.5% 21.7% 3
TENDIA 2015 Anti-Diabetes Teneligliptin 399.7 38.9% * 55.4% * 4
ROSIFLEX 2013 Anti-Arthritic Rosa Canina extract 383.4 203.8% # 82.5% 1
LNBLOC 2012 Hypertension Cilnidipine 373.5 122.0% 66.7% 2
ATORSAVE 2007 Lipid Lowering Atorvastatin 327.7 2.8% 0.2% 7
RARICAP 1990 Iron supplement Conventional Iron 263.8 10.6% 8.9% 9
CYBLEX 2014 Anti-Diabetes Gliclazide 226.8 362.4% 12.9% 5
CREVAST 2010 Lipid Lowering Rosuvastatin 218.0 14.8% 20.0% 8
MARZON 2011 Anti-infectives Sultamicillin 140.4 0.0% 10.1% 1

Source: IMS TSA and Medical Audit MAT, Mar 2018
*Growth over FY 17 considered since brand launched post MAT Mar 15
# IMS data unavailable pre 2015